Pediatric Hematology/Oncology Seminar and Workshops Announced

Publication
Article
OncologyONCOLOGY Vol 12 No 10
Volume 12
Issue 10

Advances in Pediatric Hematology/Oncology will be held November 19 through 21, 1998, at the Hilton Clearwater Beach Resort, Florida (formerly the DoubleTree). Topics presented by nationally renowned speakers include:

Advances in Pediatric Hematology/Oncology will be held November 19 through 21, 1998, at the Hilton Clearwater Beach Resort, Florida (formerly the DoubleTree). Topics presented by nationally renowned speakers include:

  • Transplantation

  • Pain management

  • Sickle cell disease

  • Immune tolerance/inhibitors

  • HIV-related malignancy

  • Pathology, new cancer agents

  • Supportive care

Representatives of various organizations will display the latest in supplies, products, and services.

Early registration fees are $130 and $50 for full-time students/residents (with accompanying letter from a faculty advisor). Please inquire about late registration fees and single-day rates.

Workshops will be held Saturday, November 21, on the topics of medical Spanish (prerequisite, knowledge of conversational Spanish) and alternative therapies for pediatric patients.

For registration forms or sponsorship opportunities please contact: The Florida Association of Pediatric Tumor Programs, P. O. Box 17757, Tampa, FL 33682-7757; phone: (813) 632-1309; e-mail: FAPTP@moffit.usf.edu.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content